| 1 |
Manufacturing and marketing of unapproved drug Meropenam 1gm + EDTA for Injection |
2024-Apr-16 |
|
366 KB |
| 2 |
Public Notice regarding DCGI meeting with Stakeholders Dated 15.04.2024 for 18 April 2024 Meeting cancellation |
2024-Apr-15 |
|
143 KB |
| 3 |
Public Notice regarding Draft CDSCO Guidance for Industry Version 1.2 |
2024-Apr-10 |
|
1184 KB |
| 4 |
Public Notice regarding DCGI meeting with Stakeholders Dated 08.04.2024 for 16 April 2024 Meeting cancellation |
2024-Apr-08 |
|
142 KB |
| 5 |
Notice to All stakeholders for Strengthening of Private Medical Device Testing Laboratory |
2024-Apr-03 |
|
388 KB |
| 6 |
Public Notice regarding DCGI meeting with Stakeholders Dated 26.03.2024 for 28 march 2024 Meeting cancellation |
2024-Mar-26 |
|
142 KB |
| 7 |
Meeting through WebEx Video-conference of the DTAB-sub Committee on 05.04.2024 at 11.00 a.m. to 6:00 p.m. to Evaluation of 16 FDCs which were earlier considered as irrational in the Expert Committee report of the Prof. Kokate Committee |
2024-Mar-22 |
|
409 KB |
| 8 |
Manufacturing and marketing of unapproved drug Meropenem & Disodium EDTA for Injection |
2024-Mar-08 |
|
383 KB |
| 9 |
Public Notice regarding DCGI meeting with Stakeholders Dated 06.03.2024 |
2024-Mar-06 |
|
106 KB |
| 10 |
Draft CDSCO Guidance for Industry: Post Approval Changes in Biological Products |
2024-Feb-28 |
|
2317 KB |
